Summary: This ADC product is comprised of an anti-CD22 monoclonal antibody (clone RFB4) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. https://www.creative-biolabs.com/adc/target-cd22-10.htm
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
